Research ArticleAutism Spectrum Disorder

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

See allHide authors and affiliations

Science Translational Medicine  08 May 2019:
Vol. 11, Issue 491, eaat7838
DOI: 10.1126/scitranslmed.aat7838

Log in to view full text

Log in through your institution

Log in through your institution

Navigate This Article